ArticleBlood advances2022

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.

Piers Blombery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.